It is worth exploring the potential benefits of GLP-1-RA as a prophylactic treatment in individuals with metabolic syndrome and a high risk of developing PCa, such as those with a strong family history of lethal PCa or who are carriers of BRCA genes. This evidence concerns the gene GCG and posterior cortical atrophy.